AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 101 min read$GRCE

Kohli Prashant purchased $214K of GRCE

Kohli Prashant (Chief Executive Officer) purchased 100,000 shares of Grace Therapeutics, Inc. (GRCE) at $2.14 ($0.21M total) on 2026-09-09.

Original reporting
SEC EDGAR · Kohli Prashant
Published Sep 10, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 11:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GRCE
Neutral
medium confidence
Mentioned
$GRCE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GRCENeutralLow
01

Why it matters

The transaction is a fresh disclosure but modest in size, offering limited trading impetus.

02

Market read

Provides a new data point for investors monitoring insider activity, but unlikely to move the stock significantly.

03

What to watch

Potential upcoming clinical data or financing events not disclosed in the filing.

Relevance 5/10Novelty 4/10Timing: today

Background

Form 4 filing from SEC EDGAR reporting an insider purchase by Grace Therapeutics' CEO.

Company-level read

Ticker impact

$GRCENeutralMedium confidence
Context

CEO Kohli Prashant bought 100,000 shares for $214,000 on 2026-09-09, increasing his stake to 121,357 shares.

Expected impact

Limited upside; may support a small price bump if market perceives it positively.

Evidence & confidence

Form 4 is a primary source, but the $214k size is small for a CEO of a mid‑cap biotech, so market reaction is likely muted.

Market effects

Sector

May be noted by biotech investors tracking insider activity, but no broader sector impact.

Regional

Minimal effect on US market overall.

Global

Limited to Grace Therapeutics shareholders.

Counterpoint

What could challenge this read

The purchase could be a routine portfolio rebalancing rather than a bullish signal.

Key entities

  • company
    Grace Therapeutics, Inc.

    Biotech firm listed on NASDAQ under ticker GRCE.

  • person
    Kohli Prashant

    Chief Executive Officer of Grace Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GRCE insider trading history →

Related articles

AUG 13
$GRCEMed

Grace Therapeutics Announces First Quarter 2027 Financial Results

Grace Therapeutics, Inc. (GRCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99. 1 Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update Princeton, NJ, August 13, 2026 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104

SEC EDGAR 8-K6 min
JUN 18
$GRCEMed

Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results

Grace Therapeutics, Inc. (GRCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20076145_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Pr

SEC EDGAR 8-K4 min
OCT 7
$LWAYLow

Divisadero Street Capital Management, LP (Zolezzi William) purchased $2.2M of LWAY (indirect holdings)

Divisadero Street Capital Management, LP purchased 103,684 indirectly-held shares of Lifeway Foods, Inc. (LWAY) at an average of $20.92 ($20.80–$21.09, $2.17M total) across 3 trades over 2026-10-02 to 2026-10-06. Filed jointly with Divisadero Street Partners GP, LLC (10% owner), Zolezzi William (10% owner), Divisadero Street Partners, L.P. (10% owner) and Divisadero Street Capital, LLC (10% owner).

SEC EDGAR1 min